A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
200
Participants
Timeline
Start Date
June 30, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Conditions
Eosinophilic Asthma Patients
Interventions
DRUG
SHR-1703 Injection
SHR-1703 Injection
All Listed Sponsors
lead
Guangdong Hengrui Pharmaceutical Co., Ltd
INDUSTRY
NCT06441812 - A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients | Biotech Hunter | Biotech Hunter